Renaissance Technologies LLC Reduces Holdings in Sotera Health Company $SHC

Key Points

• Renaissance Technologies cut its Sotera Health stake by 52.4% in the first quarter, selling 223,700 shares and retaining 203,078 shares valued at approximately $2.9 million. Institutional investors still own 91.03% of the company.
• Sotera Health exceeded second-quarter expectations, reporting adjusted EPS of $0.26 and revenue of $321.4 million, up 9.2% year over year. Management raised its full-year 2026 outlook for revenue, EBITDA and adjusted EPS.
• Analyst sentiment remains generally positive, with a consensus “Moderate Buy” rating and a $21.50 target, but debt, litigation, regulatory exposure and valuation concerns remain potential risks; an insider also sold 12.7 million shares for approximately $193.2 million.

Renaissance Technologies LLC trimmed its holdings in shares of Sotera Health Company (NASDAQ:SHC - Free Report) by 52.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 203,078 shares of the company's stock after selling 223,700 shares during the quarter. Renaissance Technologies LLC owned approximately 0.07% of Sotera Health worth $2,912,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. IFP Advisors Inc boosted its stake in shares of Sotera Health by 1,105.6% during the 4th quarter. IFP Advisors Inc now owns 1,495 shares of the company's stock worth $26,000 after acquiring an additional 1,371 shares during the last quarter. Rothschild Investment LLC bought a new stake in shares of Sotera Health during the 4th quarter valued at $27,000. Root Financial Partners LLC increased its stake in shares of Sotera Health by 217.5% in the 1st quarter. Root Financial Partners LLC now owns 2,124 shares of the company's stock worth $30,000 after purchasing an additional 1,455 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in shares of Sotera Health by 831.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,288 shares of the company's stock worth $37,000 after purchasing an additional 2,935 shares in the last quarter. Finally, Eurizon Capital SGR S.p.A. bought a new position in Sotera Health in the 4th quarter worth $40,000. 91.03% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Gtcr Investment Xi Llc sold 12,735,301 shares of the business's stock in a transaction that occurred on Wednesday, May 13th. The stock was sold at an average price of $15.17, for a total value of $193,194,516.17. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 15.36% of the company's stock.

Key Sotera Health News

Here are the key news stories impacting Sotera Health this week:

• Positive Sentiment: Strong Q2 results and raised outlook: Sotera Health reported adjusted EPS of $0.26, above the $0.24 consensus, while revenue increased 9.2% year over year to $321.4 million, exceeding estimates of $309.7 million. Adjusted EBITDA rose 10%, and net income increased to $53.6 million from $8.0 million a year earlier. Sotera Health Delivers Strong Second-Quarter and First-Half 2026 Results and Raises FY 2026 Outlook
• Positive Sentiment: Management raised full-year 2026 guidance: The company increased its constant-currency revenue growth outlook to 5.25%-6.75%, adjusted EBITDA growth outlook to 5.75%-7.25%, and adjusted EPS guidance to $0.95-$1.01. It also expects lower interest expense following a term-loan repricing that should save approximately $3.5 million annually. Sotera Health Company Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: Piper Sandler became more bullish: The firm reaffirmed its “overweight” rating and raised its price target from $22 to $25, implying substantial upside from the recent trading level. Benzinga analyst update
• Neutral Sentiment: JPMorgan’s target increase was less constructive: JPMorgan lifted its target from $16 to $18 but maintained a “neutral” rating, leaving its target below the current share price. This may be limiting enthusiasm following the earnings-driven rally. Benzinga analyst update
• Negative Sentiment: Leverage and ongoing risks remain: SHC still carries approximately $2.2 billion of debt, while litigation related to ethylene oxide facilities, inflationary costs and regulatory risks remain potential overhangs. The stock’s valuation also appears demanding relative to JPMorgan’s neutral view.

Sotera Health Trading Down 0.3%

Shares of SHC stock opened at $18.86 on Friday. The company has a debt-to-equity ratio of 3.19, a quick ratio of 2.54 and a current ratio of 2.80. The stock has a fifty day simple moving average of $17.13 and a two-hundred day simple moving average of $16.33. The firm has a market capitalization of $5.38 billion, a PE ratio of 33.09 and a beta of 1.77. Sotera Health Company has a 52-week low of $12.94 and a 52-week high of $19.85.

Sotera Health (NASDAQ:SHC - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.24 by $0.02. The business had revenue of $321.38 million for the quarter, compared to the consensus estimate of $309.70 million. Sotera Health had a return on equity of 40.12% and a net margin of 13.44%.The business's revenue was up 9.2% on a year-over-year basis. During the same period in the previous year, the business earned $0.20 earnings per share. Sotera Health has set its FY 2026 guidance at 0.950-1.010 EPS. On average, analysts predict that Sotera Health Company will post 0.87 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. Barclays lifted their target price on Sotera Health from $19.00 to $22.00 and gave the company an "overweight" rating in a research report on Friday. Wall Street Zen cut Sotera Health from a "strong-buy" rating to a "buy" rating in a research report on Saturday, April 11th. Weiss Ratings raised Sotera Health from a "hold (c-)" rating to a "hold (c)" rating in a research note on Thursday, July 9th. UBS Group set a $19.00 price objective on Sotera Health in a research report on Wednesday, June 24th. Finally, JPMorgan Chase & Co. boosted their price objective on Sotera Health from $16.00 to $18.00 and gave the company a "neutral" rating in a research note on Friday. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $21.50.

Sotera Health Profile

Sotera Health Inc NASDAQ: SHC is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.

Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source